Medochemie Ltd. is an international pharmaceutical company headquartered in Limassol, Cyprus. Founded in 1976 by Dr. Andreas Pittas, the company is dedicated to providing high-quality, affordable generic medicines and super-generic pharmaceutical products. Medochemie has a strong global presence, with its products marketed in over 107 countries and a network of 21 overseas offices. The company operates 13 state-of-the-art manufacturing facilities and is committed to research, development, and adherence to strict quality standards.
The headquarters serves as the central hub for Medochemie's global operations, including strategic planning, corporate management, international sales and marketing, finance, research and development oversight, and regulatory affairs.
The headquarters likely houses advanced administrative offices, and potentially R&D and quality control laboratories, reflecting the company's commitment to innovation and quality. Facilities are modern and compliant with pharmaceutical industry standards.
The work culture at Medochemie's HQ is expected to be professional, quality-focused, and aligned with the pharmaceutical industry's rigorous standards. It likely fosters innovation, collaboration, and a commitment to improving global health through accessible medicines.
The Limassol headquarters is significant as the birthplace and central nervous system of Medochemie, driving its international expansion and commitment to producing affordable pharmaceuticals. It symbolizes Cyprus's capability in the global pharmaceutical sector.
Medochemie Ltd. maintains a robust global presence, with its pharmaceutical products marketed in over 107 countries across five continents. The company supports this reach through 13 modern manufacturing plants located in Cyprus (9), The Netherlands (1), and Vietnam (3), along with a network of 21 strategically located overseas offices. Globally supported functions include research & development, manufacturing, quality assurance, regulatory affairs, international sales & marketing, distribution, and pharmacovigilance, ensuring comprehensive operational capabilities worldwide.
1-10 Constantinoupoleos Street, Industrial Area
Limassol
Limassol District
Cyprus
Address: MEDOCHEMIE (FAR EAST) LTD., No. 40, VSIP II-A, Street No. 27, Vietnam-Singapore Industrial Park II-A, Tan Uyen Town, Binh Duong Province, Vietnam
To supply high-quality, affordable medicines to Vietnam and the broader Southeast Asian region, enhancing Medochemie's supply chain resilience and market responsiveness in Asia.
Address: 96 Vouliagmenis Ave. & 2 Skyllakou Str., 16675 Glyfada, Athens, Greece
To strengthen Medochemie's market presence in Greece and the Balkan region, ensuring product availability, providing local customer support, and navigating regional healthcare regulations.
Address: Mast Multinational B.V. (part of Medochemie Group), Koperslager 7, 3891 EG Zeewolde, The Netherlands
To serve the European market with locally manufactured pharmaceuticals, ensuring compliance with EU GMP standards and facilitating efficient distribution across Europe.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Medochemie Ltd' leadership includes:
Medochemie Ltd has been backed by several prominent investors over the years, including:
No major publicly announced executive hires, exits, or significant transitions have been identified for Medochemie Ltd. in the last 12 months. The company's leadership team appears stable.
Discover the tools Medochemie Ltd uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Medochemie Ltd. typically uses standard professional email formats. Common patterns include combinations of the employee's first name, last name, or initials, followed by the @medochemie.com domain.
[first].[last]@medochemie.com or [first_initial][last]@medochemie.com
Format
jane.doe@medochemie.com or jdoe@medochemie.com
Example
75%
Success rate
Financial Mirror • March 12, 2024
Medochemie is investing EUR 30 million to construct a new manufacturing plant in Cyprus dedicated to producing sterile penicillin products, aiming to address potential antibiotic shortages in Europe and enhance its production capabilities....more
Cyprus Mail • June 2, 2023
Medochemie announced a significant investment of €35 million in a new state-of-the-art Research and Development centre in Limassol, Cyprus. This facility aims to enhance the company's capabilities in developing innovative and high-quality generic medicines....more
Medochemie Website • February 20, 2024
Medochemie received three awards at the 12th INBusiness GroceryRetail Awards, recognizing its excellence in product quality and contribution to the Cypriot market. The awards highlight the company's commitment to providing high-standard pharmaceutical products....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Medochemie Ltd, are just a search away.